|
|
|
|
|
|
|
|
Abstract
Highlights
- •
- Ovarian cancer (OvCa) is the most lethal gynecological malignancy.
- •
- No adequate screening or diagnostic tools exist for early stage OvCa diagnosis.
- •
- FOLR1 appears to be a promising novel (new) serological biomarker for ovarian cancer.
Objectives
Ovarian
cancer is the most lethal gynecological malignancy in North America.
Although survival rates are high when the disease is diagnosed at an
early stage, this decreases exponentially in late-stage diagnoses. As
such, there is a need for novel early detection biomarkers. Through an
integrated approach to ovarian cancer biomarker discovery that combines
proteomics with transcriptomics and bioinformatics, our laboratory has
identified folate-receptor 1 (FOLR1) and Dickkopf-related protein 3
(Dkk-3) as putative biomarkers. The objective of this study was to
measure the levels of FOLR1 and Dkk-3 in the serum of patients with
ovarian cancer, benign gynecological conditions and healthy women.
Design and methods
FOLR1
and Dkk-3 were analyzed in serum of 100 ovarian cancer patients, 100
patients with benign gynecological conditions, and 100 healthy women
using enzyme-linked immunosorbent assays (ELISAs). All specimens were
analyzed in triplicate.
Results
FOLR1
was significantly elevated in the serum of ovarian cancer patients
compared to serum of both healthy controls (P < 0.0001) and patients
with benign gynecological conditions (P < 0.0001). Furthermore, FOLR1
was strongly correlated with CA125 as both were elevated in the serous
histotype and in late-stage disease. FOLR1 did not outperform CA125 in
receiver operating characteristic curve analysis and there was no
significant complementarity between the two markers. Dkk-3 was not
significantly different between the three serum cohorts and was not
correlated with CA125.
Conclusions
FOLR1
is a new biomarker for ovarian cancer which correlates closely with
CA125. The role of FOLR1 in the pathogenesis of ovarian cancer warrants
further investigation.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.